Invivyd’s stock plunged 21.1% following its Q1 2026 earnings release, driven primarily by a cautious outlook amid slowing COVID vaccine revenues and concerns over margin pressures, despite ongoing monoclonal antibody revenue growth.

• Monoclonal antibody revenues continued to grow, offsetting declines in COVID vaccine utilization and associated revenue.
• The company slowed recruitment in its DECLARATION pivotal study to align with seasonal COVID-19 waves, potentially signaling challenges in near-term growth visibility.
• Management highlighted increased government affairs activity but did not provide concrete guidance upgrades, reflecting a measured tone on near-term prospects.
• The neutralization confirmation against Omicron BA.3.2 was acknowledged but seen as less impactful given the variant’s limited clinical threat.
• Early pipeline expansion was noted, but no immediate commercial catalysts were detailed, leaving investor focus on current performance and near-term outlook.